| 1. |
www.fondazioneicona.org |
|
| 2. |
Notiziario dell’Istituto Superiore di Sanità, Supplemento 23, N4, 1-2010 |
|
| 3. |
Bridge DA, et al. Clinicians fail to routinely provide reproduction counseling to HIV infected women in the United States. IAS Mexico City 2008, TUPE0911 |
|
| 4. |
Floridia M et al, Antiretroviral therapy at conception in pregnant women with HIV in Italy: wide range of variability and frequent exposure to contraindicated drugs. Antivir Ther. 2006;11(7):941-6. |
|
| 5. |
Floridia M et al, Treatment change in pregnancy is a significant risk factor for detectable HIV-1 RNA in plasma at end of pregnancy. HIV Clin Trials. 2010 Nov-Dec;11(6):303-11. |
|
| 6. |
Public Health Service Task Force Recommendations: Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women; 24-May 2010 |
|
| 7. |
European AIDS Clinical Society Guidelines |
|
| 8. |
de Ruiter A, et al. British HIV Association and Children’s HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV Medicine 2008;9:452-502 |
|
| 9. |
Linee Guida Italiane sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV- 1 |
|
| 10. |
Kaletra - Summary of Products Characteristics |
|
| 11. |
Robert SS et al, Lopinavir/ritonavir in pregnancy. J Acquir Immune Defic Syndr. 2009 Aug 1;51(4):456-61. |
|
| 12. |
Kiser J, et al. Total and Unbound Lopinavir/Ritonavir Pharmacokinetics in a Concentration-guided Study of HIV-infected Women throughout Pregnancy and Post-partum. 16th CROI, Montreal 2009, #946 |
|
| 13. |
Best BM et al. Lopinavir tablet pharmacokinetics with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2010;54:381–388. |
|
| 14. |
Cressey T et al, Pharmacokinetics and virologic response of zidovudine/lopinavir/ritonavir initiated during the third trimester of pregnancy. AIDS 2010, 24:2193–2200 |
|
| 15. |
Patterson K, et al. Pharmacokinetics of the LPV/r Tablet in HIV-infected Pregnant Women: A Longitudinal Investigation of Protein Bound and Unbound Drug Exposure with Empiric Dosage Adjustment. 18th CROI 2011, Poster # 645 |
|
| 16. |
Hermes A et al, Efficacy, Safety and Tolerability of Lopinavir/ritonavir (LPV/r) in HIV-Infected Women: Results of a Meta-Analysis of 7 Prospective, Randomized Clinical Trials (RCTs) Through 48 Weeks, presentato al 1st International Workshop on HIV & Women from Adolescence through Menopause. Washington DC, January 10 - 11, 2011 |
|
| 17. |
Lockman S et al, Antiretroviral Therapies in Women after Single-Dose Nevirapine Exposure, New England Journal of Medicine, 2010; 363;1499-1509 |
|
| 18. |
APR - Antiretroviral Pregnancy Registry International Interim Report for 1-Jan 1989 - 31 July 2010. Jan 2011 |
|
| 19. |
Barocelli S et al, Antiretroviral treatment in pregnancy: a six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes AIDS Patient Care STDS. 2009 Jul;23(7):513-20. |
